Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?

Date publication

février 2016

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GEOFFROIS Lionnel

Tous les auteurs :
Pouessel D, Chevret S, Rolland F, Gravis G, Geoffrois L, Roubaud G, Terrisse S, Boyle H, Chevreau C, Dauba J, Moriceau G, Alexandre I, Deplanque G, Chapelle A, Vauleon E, Colau A, Audenet F, Grellety T, Culine S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26724422

Résumé

There is continuing controversy regarding the optimal regimen for neoadjuvant chemotherapy (NAC) in bladder cancer.

Mots clés

Aged, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Chemotherapy, Adjuvant, Cisplatin, administration & dosage, Cystectomy, Doxorubicin, administration & dosage, Drug Administration Schedule, Female, France, Humans, Kaplan-Meier Estimate, Male, Methotrexate, administration & dosage, Middle Aged, Neoadjuvant Therapy, adverse effects, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Urinary Bladder Neoplasms, drug therapy, Urothelium, drug effects, Vinblastine, administration & dosage

Référence

Eur. J. Cancer. 2016 Feb;54:69-74